Gain TherapeuticsGANX
13F holders, Q1 2026 (March 31)At the end of Q1 2026, 42 institutions reported holding Gain Therapeutics Inc. (GANX) in their 13F filings, down 6 from Q4 2025. 7 opened new positions and 15 sold out. The largest holders were Marshall Wace, LLP ($3.4M), Potomac Capital Management, Inc. ($2.0M) and Jones Financial Companies LLLP ($1.2M). 2 famous investors held it, including David Einhorn (0.0% of Greenlight Capital (DME Capital Management)'s portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Gain Therapeutics Inc.
- CUSIP
- 36269B105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $404K |
| Exits | 15 | $1.1M |
All 13F filers, Q4 2025 → Q1 2026: 856,221 shares bought and 797,882 shares sold, net +58,339 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 42 holders
| Marshall Wace, LLP | 0.00% | Add +6.5% | 1,769,788 | $3.4M |
| Potomac Capital Management, Inc. | 1.71% | Reduce -0.1% | 1,008,600 | $2.0M |
| Jones Financial Companies LLLP | 0.00% | Reduce -10.1% | 631,615 | $1.2M |
| Cambridge Investment Research Advisors, Inc. | 0.00% | No change | 568,645 | $1.1M |
| Greenlight Capital (DME Capital Management) | 0.03% | No change | 566,130 | $1.1M |
| Geode Capital Management, LLC | 0.00% | Add +12.4% | 447,342 | $869K |
| Susquehanna International Group, LLP | 0.00% | Reduce -37.0% | 431,267 | $837K |
| Vanguard Capital Management LLC | 0.00% | — | 399,886 | $776K |
| Gsa Capital Partners LLP | 0.04% | Add +1426.3% | 312,467 | $606K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 229,979 | $446K |
| BlackRock, Inc. | 0.00% | Add +7.4% | 225,046 | $437K |
| UBS Group AG | 0.00% | Add +171.8% | 220,489 | $428K |
| Jane Street Group, LLC | 0.00% | Reduce -10.5% | 216,883 | $421K |
| Cresset Asset Management, LLC | 0.00% | No change | 160,000 | $310K |
| State Street Corp. | 0.00% | No change | 157,537 | $306K |
| Morgan Stanley | 0.00% | Reduce -5.4% | 139,652 | $271K |
| Stratos Wealth Partners, LTD. | 0.00% | New | 131,621 | $255K |
| Northern Trust Corp. | 0.00% | Add +11.8% | 113,997 | $221K |
| LPL Financial LLC | 0.00% | Reduce -2.2% | 104,251 | $202K |
| Prelude Capital Management, LLC | 0.01% | No change | 35,820 | $69K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 30,004 | $58K |
| Commonwealth Equity Services, LLC | 0.00% | Add +134.2% | 29,703 | $58K |
| Apollon Wealth Management, LLC | 0.00% | Add +33.7% | 26,500 | $51K |
| Citadel Advisors | 0.00% | New | 24,900 | $48K |
| Schonfeld Strategic Advisors LLC | 0.00% | New | 24,500 | $48K |
| Oliver Luxxe Assets LLC | 0.01% | No change | 20,250 | $39K |
| Vanguard Global Advisers, LLC | 0.00% | — | 18,376 | $36K |
| Wealthspire Advisors, LLC | 0.00% | No change | 16,900 | $33K |
| Benedict Financial Advisors Inc. | 0.01% | Reduce -59.2% | 15,500 | $30K |
| Sandhill Capital Partners LLC | 0.00% | No change | 15,400 | $30K |
| Millington Financial Advisors, LLC | 0.01% | New | 15,000 | $29K |
| Wealth Enhancement Advisory Services, LLC | 0.00% | No change | 15,556 | $29K |
| Simplex Trading, LLC | 0.00% | Reduce -72.0% | 13,439 | $26K |
| Kestra Advisory Services, LLC | 0.00% | No change | 12,000 | $23K |
| Wells Fargo & Company | 0.00% | Add +317.0% | 11,050 | $21K |
| Virtu Financial LLC | 0.00% | New | 10,685 | $21K |
| NewEdge Advisors, LLC | 0.00% | No change | 10,600 | $21K |
| Group One Trading LLC | 0.00% | Reduce -88.2% | 6,404 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -19.7% | 5,506 | $11K |
| JPMorgan Chase & Co. | 0.00% | New | 1,700 | $3K |
| Larson Financial Group LLC | 0.00% | No change | 10 | $19 |
| Citigroup Inc. | 0.00% | New | 1 | $2 |
"% of holder's portfolio" is GANX's weight in each manager's 13F, not the share of Gain Therapeutics Inc. the manager owns.